Will HRTX's Q1 2025 earnings beat forecasts like Q4 2024?

**Heron Therapeutics (HRTX) is likely to experience a decline in earnings for Q1 2025 compared to Q4 2024**, based on the following points: 1. **Expected Earnings Per Share (EPS)**: - For Q1 2025, analysts forecast an EPS of $0.01. - In Q4 2024, HRTX reported an EPS of $0.02. - This indicates a potential decrease in earnings per share from the previous quarter. 2. **Revenue Comparison**: - The projected revenue for Q1 2025 is $37.37 million. - HRTX's revenue for Q4 2024 was $40.78 million. - Although the company is expected to show revenue growth, the increase might not be sufficient to surpass the previous quarter's revenue. 3. **Market Analysts' Sentiments**: - Recent research notes suggest that some analysts have downgraded their ratings or reduced their price targets for HRTX. This could reflect a more cautious outlook on the company's short-term performance. 4. **Historical Performance and Challenges**: - HRTX faced increased competition for one of its products in Q4 2024, which could impact net revenues in Q1 2025. - The company also had to deal with inventory write-offs and impairment write-offs in Q4 2024, which might indicate underlying challenges that could affect financial performance in the upcoming quarter. In conclusion, while HRTX might show some growth in revenue, the EPS is expected to decline, and the overall financial performance in Q1 2025 is likely to be softer compared to the strong results in Q4 2024.